| Mr Alan Lee Armentrout, NP-C | |
|
8200 N Macarthur Blvd, Irving, TX 75063-4889 | |
| (972) 975-2324 | |
| Not Available |
| Full Name | Mr Alan Lee Armentrout |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 8200 N Macarthur Blvd, Irving, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023128048 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | DC3078 (Texas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | AP129669 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Primary Health Physicians Pllc | 7810237740 | 146 |
News Archive
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
At the upcoming 100th Scientific Assembly and Annual Meeting of RSNA, ContextVision, will launch a new groundbreaking product range for 3D ultrasound. The new second generation of 3D volume processing and the photo-like 3D rendering software provides new features that brings 3D imaging to a higher level. The products offer a higher diagnostic value and support further use of 3D ultrasound.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66® cell line.
A Florida businessman filed suit today against Atkins Nutritionals, Inc., and the Estate of Dr. Robert C. Atkins, claiming that the late diet author's controversial high-fat, low-carbohydrate regimen caused severe heart disease, necessitating angioplasty and a stent. He is seeking a court injunction banning Atkins Nutritionals from marketing its products without a warning of potential health risks and asks for compensatory damages.
› Verified 4 days ago
| Provider Name | Primary Health Physicians Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1770048704 PECOS PAC ID: 7810237740 Enrollment ID: O20190312003418 |
News Archive
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
At the upcoming 100th Scientific Assembly and Annual Meeting of RSNA, ContextVision, will launch a new groundbreaking product range for 3D ultrasound. The new second generation of 3D volume processing and the photo-like 3D rendering software provides new features that brings 3D imaging to a higher level. The products offer a higher diagnostic value and support further use of 3D ultrasound.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66® cell line.
A Florida businessman filed suit today against Atkins Nutritionals, Inc., and the Estate of Dr. Robert C. Atkins, claiming that the late diet author's controversial high-fat, low-carbohydrate regimen caused severe heart disease, necessitating angioplasty and a stent. He is seeking a court injunction banning Atkins Nutritionals from marketing its products without a warning of potential health risks and asks for compensatory damages.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Alan Lee Armentrout, NP-C 3329 Kelsey Ct, Flower Mound, TX 75028-2935 Ph: (972) 975-2324 | Mr Alan Lee Armentrout, NP-C 8200 N Macarthur Blvd, Irving, TX 75063-4889 Ph: (972) 975-2324 |
News Archive
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
At the upcoming 100th Scientific Assembly and Annual Meeting of RSNA, ContextVision, will launch a new groundbreaking product range for 3D ultrasound. The new second generation of 3D volume processing and the photo-like 3D rendering software provides new features that brings 3D imaging to a higher level. The products offer a higher diagnostic value and support further use of 3D ultrasound.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66® cell line.
A Florida businessman filed suit today against Atkins Nutritionals, Inc., and the Estate of Dr. Robert C. Atkins, claiming that the late diet author's controversial high-fat, low-carbohydrate regimen caused severe heart disease, necessitating angioplasty and a stent. He is seeking a court injunction banning Atkins Nutritionals from marketing its products without a warning of potential health risks and asks for compensatory damages.
› Verified 4 days ago